$43.39▴ 0.70%
End-of-day close · 2026-09-01
What most investors miss
Trends, drivers and alerts — the full picture.
Profit → Cash
Not enough data yet
Valuation
Not enough data yet
Not enough valuation history to place this in context.
Revenue growth
Not enough data yet
Not enough revenue history to measure growth.
Leverage
Not enough data yet
More coming: dilution / share-count creep.
✦ The read
UroGen Pharma Ltd.'s earnings-quality signal is not available yet.
Key numbers
Recent news
Take the Zacks Approach to Beat the Markets: Oportun Financial, Uranium Royalty & Amgen in FocusUroGen Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
UroGen's Chief Medical Officer Sold $400,000 in Stock After a 191% Run
Is UroGen Pharma a Stock to Sell After Its Chief Medical Officer Unloaded 5,222 Shares?